GoAI
Get started
China Health Group Limited logo

China Health Group Limited

0673.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$0.325

+HK$0.03 · +10.17%

Aug 24, 2:31 PM HKT

0673.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Serving as an investment holding company, China Health Group Limited engages in a diverse range of operations. Within the People's Republic of China, its core business involves the supply and maintenance of medical equipment and disposables, coupled with the administration and operation of healthcare facilities. The company also extends its activities into commercial factoring and real estate investment. Previously operating under the name China HealthCare Holdings Limited, the company officially adopted "China Health Group Limited" in September 2015. Its principal office is located in Central, Hong Kong.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
HK
CEO
Chung
Listed since
Oct 14, 1996
Employees
111

Market position

Day range

Current HK$0.325

52-week range

Current HK$0.325

Open
HK$0.38
Previous close
HK$0.295
Volume
12K
0.14× average
Average volume
86.5K
Average daily volume
Market cap
450.82M HKD
Beta
-1.14
Market reference 1
50-day average
HK$0.4173
-22.12% below average
200-day average
HK$0.5734
-43.32% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
485.48M HKD
P/E (TTM)
-6.62×
P/B (TTM)
8.46×
P/S (TTM)
10.97×
EV / EBITDA
-11.2×
Earnings yield
-9.53%
Free cash flow yield
-17.16%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
17.35%
Operating margin
-110.56%
Net margin
-117.80%
Return on equity
-89.97%
Return on assets
-30.42%
Return on invested capital
-68.82%

Financial health

Debt / equity
0.09×
Current ratio
1.24×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends57%-27%-111%-195%Gross margin, FY2021: 26.81%Gross margin, FY2022: 35.59%Gross margin, FY2023: 22.76%Gross margin, FY2024: 23.71%Gross margin, FY2025: 17.35%Operating margin, FY2021: -12.99%Operating margin, FY2022: -21.34%Operating margin, FY2023: -62.87%Operating margin, FY2024: -172.37%Operating margin, FY2025: -110.56%Net margin, FY2021: -11.40%Net margin, FY2022: -55.02%Net margin, FY2023: -67.06%Net margin, FY2024: -174.07%Net margin, FY2025: -116.65%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 26.81%. Gross margin FY2022 35.59%. Gross margin FY2023 22.76%. Gross margin FY2024 23.71%. Gross margin FY2025 17.35%. Operating margin FY2021 -12.99%. Operating margin FY2022 -21.34%. Operating margin FY2023 -62.87%. Operating margin FY2024 -172.37%. Operating margin FY2025 -110.56%. Net margin FY2021 -11.40%. Net margin FY2022 -55.02%. Net margin FY2023 -67.06%. Net margin FY2024 -174.07%. Net margin FY2025 -116.65%.

Income trends

Revenue

41.09M HKD+5.52%

Operating income

−45.43M HKD+32.32%

Net income

−47.93M HKD+29.29%
Income trends across reported periods124.51M HKD54.58M HKD−15.35M HKD−85.27M HKDRevenue, FY2021: 107.03M HKDRevenue, FY2022: 76.41M HKDRevenue, FY2023: 59.93M HKDRevenue, FY2024: 38.94M HKDRevenue, FY2025: 41.09M HKDOperating income, FY2021: −13.9M HKDOperating income, FY2022: −16.31M HKDOperating income, FY2023: −37.68M HKDOperating income, FY2024: −67.13M HKDOperating income, FY2025: −45.43M HKDNet income, FY2021: −12.21M HKDNet income, FY2022: −42.05M HKDNet income, FY2023: −40.19M HKDNet income, FY2024: −67.79M HKDNet income, FY2025: −47.93M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 107.03M HKD. Revenue FY2022 76.41M HKD. Revenue FY2023 59.93M HKD. Revenue FY2024 38.94M HKD. Revenue FY2025 41.09M HKD. Operating income FY2021 −13.9M HKD. Operating income FY2022 −16.31M HKD. Operating income FY2023 −37.68M HKD. Operating income FY2024 −67.13M HKD. Operating income FY2025 −45.43M HKD. Net income FY2021 −12.21M HKD. Net income FY2022 −42.05M HKD. Net income FY2023 −40.19M HKD. Net income FY2024 −67.79M HKD. Net income FY2025 −47.93M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue41.09M HKD38.94M HKD59.93M HKD76.41M HKD107.03M HKD
Cost of goods sold33.96M HKD29.71M HKD46.29M HKD49.22M HKD78.34M HKD
Gross profit7.13M HKD9.24M HKD13.64M HKD27.19M HKD28.69M HKD
Selling, general, and administrative52.56M HKD68.83M HKD51.08M HKD39.99M HKD39.52M HKD
Operating expenses52.56M HKD76.36M HKD49.75M HKD43.5M HKD42.59M HKD
Interest income1K HKD9K HKD920K HKD439K HKD333K HKD
Interest expense187K HKD252K HKD327K HKD2.19M HKD293K HKD
Depreciation and amortization2.09M HKD3.41M HKD4.55M HKD4.15M HKD4.03M HKD
Operating income−45.43M HKD−67.13M HKD−37.68M HKD−16.31M HKD−13.9M HKD
Net income−47.93M HKD−67.79M HKD−40.19M HKD−42.05M HKD−12.21M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.04

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.01-0.04-0.07-0.11Q1 '21Q3 '21Q1 '22Q4 '22Q3 '23Q4 '23Q2 '24Q4 '24
Q1 2021, reported Mar 31, 2021: actual -0.009, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual -0.013, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual -0.017, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 1, 2022: actual -0.066, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Jul 1, 2023: actual -0.032, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 30, 2023: actual -0.032, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 28, 2024: actual -0.052, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual -0.036, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates68.71M51.1M33.49M15.88MQ1 '21Q3 '21Q1 '22Q4 '22Q3 '23Q4 '23Q2 '24Q4 '24
Q1 2021, reported Mar 31, 2021: actual 54.48M HKD, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual 42.02M HKD, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual 65M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Dec 1, 2022: actual 32.32M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Jul 1, 2023: actual 44.09M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 30, 2023: actual 30.34M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 28, 2024: actual 29.59M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual 18.68M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Aug 8, 2022

1:10

0673.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.66

-3.20%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.42

-5.06%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.10

-5.99%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.45

-2.88%

Continue in GoAI

Research 0673.HK

research.disclaimer